Yazar "Erkaya, Salim" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe BORDERLINE OVARIAN TUMORS (BOT); SINGLE CENTER EXPERIENCE OF 183 CASES(Lippincott Williams & Wilkins, 2013) Güngör, Tayfun; Çetinkaya, Nilüfer; Çağlar, Mete; Yalçın, Hakan; Özdal, Bülent; Bayramoğlu, H.; Erkaya, Salim…Öğe CONCOMITANT IPSILATERAL OVARIAN PATHOLOGIES OF BORDERLINE OVARIAN TUMORS (BOT); SINGLE CENTER EXPERIENCE OF 183 CASES SINCE 1999(Lippincott Williams & Wilkins, 2013) Erkaya, Salim; Çetinkaya, Nilüfer; Uygur, D.; Akbay, S.; Çağlar, Mete; Özdal, Bülent; Güngör, Tayfun…Öğe CONCOMITANT UTERINE PATHOLOGIES OF BORDERLINE OVARIAN TUMORS (BOT); SINGLE CENTER EXPERIENCE OF 183 CASES(Lippincott Williams & Wilkins, 2013) Güngör, Tayfun; Çetinkaya, Nilüfer; Özdal, Bülent; Tuğ, M.; Çağlar, Mete; Erkaya, Salim…Öğe FATES OF APPENDECTOMY AND OMENTECTOMY SPECIMENS FOLLOWING BORDERLINE OVARIAN TUMORS (BOT); SINGLE CENTER EXPERIENCE OF 183 CASES(Lippincott Williams & Wilkins, 2013) Güngör, Tayfun; Çetinkaya, Nilüfer; Çağlar, Mete; Yalçın, Hakan; Özdal, Bülent; Bayramoğlu, H.; Erkaya, Salim…Öğe Is Target Oriented Surgery Sufficient with Borderline Ovarian Tumors? - Role of Accompanying Pathologies(Asian Pacific Organization Cancer Prevention, 2014) Güngör, Tayfun; Çetinkaya, Nilufer; Yalçın, Hakan; Özdal, Bülent; Özgü, Emre; Başer, Eralp; Erkaya, SalimBackground: There are limited data in the literature related to concomitant genital or extra-genital organ pathologies in patients with borderline ovarian tumors (BOTs). The aim of this study was to evaluate our experience with 183 patients to draw attention to the accompanying organ pathologies with BOTs. Materials and Methods: One hundred eighty-three patients with BOTs, diagnosed and/or treated in our center between January of 2000 and March of 2013 were evaluated retrospectively. Data related to age, tumor histology, lesion side, disease stage, accompanying incidental ipsilateral and/or contralateral ovarian pathologies, treatment approaches, and follow-up periods were investigated. Incidental gynecologic and non-gynecologic concomitant organ pathologies were also recorded. Results: The mean age at diagnosis was 40.6 years (range: 17-78). Ninety-five patients (51%) were <= 40 years. A hundred and forty-seven patients (80%) were at stage IA of the disease. The most common type of BOT was serous in histology. Non-invasive tumor implants were diagnosed in 4% and uterine involvement was found 2% among patients who underwent hysterectomies. There were 12 patients with positive peritoneal washings. Only 17 and 84 patients respectively had concomitant ipsilateral and concomitant contralateral incidental ovarian pathologies. The most common type of uterine, appendicular and omental pathologies were chronic cervicitis, lymphoid hyperplasia and chronic inflammatory reaction. Conclusions: According to our findings most of accompanying pathologies for BOT are benign in nature. Nevertheless, there were additional malignant diseases necessitating further therapy. We emphasize the importance of the evaluation of all abdominal organs during surgery.Öğe Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases(Springer Heidelberg, 2015) Güngör, Tayfun; Çetinkaya, Nilufer; Yalçın, Hakan; Özdal, Bülent; Özgü, Emre; Başer, Eralp; Erkaya, SalimBorderline ovarian tumors (BOTs) constitute about a quarter of epithelial ovarian malignancies and require different treatment approaches. The present study aims to document the experience of a single center on the treatment outcome of women who had conservative or comprehensive surgery for BOTs. One hundred eighty-three patients with BOTs, diagnosed and/or treated in our center between January of 2000 and March of 2013, were reviewed retrospectively. The mean age at diagnosis was 40.6 years old (range 17-78). Ninety-five patients (51 %) were a parts per thousand currency sign40 years. Comprehensive surgical staging and fertility sparing surgery were performed in 49 % (n = 91) and 48 % of patients (n = 89) respectively. A hundred and forty-seven patients had stage IA disease (80 %). The most common type of BOT was serous in histology with 18 % bilateralism. CA-125 and CA-199 levels were increased in 29 (19 %) and 15 (10 %) patients with stage IA disease. Non-invasive tumor implants were diagnosed in 9 patients (4 %) and uterine involvement was 2 % among BOT patients that underwent hysterectomies. The mean post-operative follow-up period was 20.4 months (range 6-78 months). Disease recurrence was seen in 5 patients indicating overall recurrence rate of 2.7 %. In our study, we evaluated a large data pool of 183 patients diagnosed with borderline epithelial ovarian tumors. BOTs have a relatively better prognosis than invasive epithelial ovarian cancer. Surgery with proper staging is the cornerstone of treatment. Patients with BOTs at the early stage can undergo fertility sparing surgery with close follow-up.
